Gene transfer to glial tumors using herpes simplex virus

Area of Science:

• Neuro-oncology
• Gene Therapy
• Virology

Background:

• Glial tumors are aggressive brain cancers with poor prognoses due to limited treatment efficacy.
• Current therapies like surgery, radiation, and chemotherapy struggle to eliminate infiltrating malignant cells, leading to inevitable recurrence.

Purpose of the Study:

• To explore gene transfer strategies for selectively killing glial tumor cells.
• To investigate the potential of replication-competent viral vectors for enhanced tumor cell eradication.

Main Methods:

• Utilizing replication-competent viral vectors, including adenovirus and herpes simplex virus (HSV).
• Engineering HSV vectors for conditional replication in dividing tumor cells but not in non-dividing neurons.
• Developing viral mutants deficient in genes like thymidine kinase (tk) or gamma34.5 for tumor-specific replication.

Main Results:

• Demonstrated pre-clinical and clinical application of viral vectors for glioblastoma treatment.
• Engineered HSV vectors exhibit tumor-selective replication, enhancing therapeutic specificity.
• Conditional replication-competent viruses show potential for tumor spread with minimized normal brain damage.

Conclusions:

• Gene therapy with engineered viral vectors offers a promising approach to target and eliminate glial tumors.
• Conditional replication-competent viruses, particularly HSV mutants, enhance treatment specificity and effectiveness.
• This strategy holds potential for improving outcomes in patients with currently fatal brain cancers.